2026-04-15T14:11:35-05:00 2025-06-30 DR-4856-CA LA Fires Maginnis Knechtel & McIntyre LLP 300 West Colorado Blvd Pasadena CA 91105 990 2024-07-01 952916590 DOHENY EYE INSTITUTE % KASHIF KHAN DOHE 3233427100 150 ORANGE GROVE AVE PASADENA CA 91103 MARISSA GOLDBERG CEO 3233427100 2026-03-19 true true Linda E G Ballesteros P00366852 6264493466 2026-03-04 2024 2025-03-06 01:10:19Z MARISSA GOLDBERG 150 ORANGE GROVE AVE PASADENA CA 91103 154052818 false X WWW.DOHENY.ORG X 1947 CA TO FURTHER THE CONSERVATION, IMPROVEMENT AND RESTORATION OF HUMAN EYESIGHT. 14 13 135 25 17362 16362 9662775 6238541 6338227 6121156 8857656 5998524 241918 1114429 25100576 19472650 0 0 0 0 13177995 14148178 0 0 1801714 8846518 9257661 22024513 23405839 3076063 -3933189 241932449 248533441 13737651 15448827 228194798 233084614 X TO FURTHER THE CONSERVATION, IMPROVEMENT AND RESTORATION OF HUMAN EYESIGHT" (MRS. DOHENY - 1947). false false 12975041 6121156 THE MISSION OF THE DOHENY EYE INSTITUTE (DEI), TO FURTHER THE CONSERVATION, IMPROVEMENT AND RESTORATION OF HUMAN EYESIGHT, IS GUIDED BY THE FOLLOWING OBJECTIVES: 1. TO INCREASE KNOWLEDGE OF THE HUMAN EYE, ITS CONDITIONS AND DISEASES, THROUGH RESEARCH; 2. TO TRANSMIT THIS KNOWLEDGE THROUGH EDUCATION, TRAINING, AND COMMUNITY SERVICE; AND 3. TO FACILITATE THE APPLICATION OF ITS RESEARCH TO IMPROVE PATIENT CARE AND FOSTER FURTHER RESEARCH. RESEARCH ACTIVITIES FOR THE PERIOD AND SELECTED FOR LONG-TERM FOCUS INCLUDE: RETINAL AND MACULAR DEGENERATION RESEARCH THROUGH THE STUDY OF RETINAL PIGMENT EPITHELIUM AND THE USE OF ADVANCED RETINAL IMAGING IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION (AMD) AND IMAGE ANALYSIS USING ARTIFICIAL INTELLEGENCE; OPTIC NERVE RESEARCH AND INVESTIGATIONS OF DISEASES INVOLVING RETINAL GANGLION CELLS; INVESTIGATIONS OF RETINAL VASCULAR STIFFNESS AND ALTERED IMMUNE CELL REGULATION AS POTENTIAL CAUSATIVE FACTORS IN DIABETIC RETINOPATHY; RESEARCH FOCUSED ON DEFINING THE MOLECULAR DETAILS LINKING MITOCHONDRIAL DYSFUNCTION AND ALTERED SIGNALING BETWEEN RETINAL NEURONS. On December 18, 2013, the Doheny Eye Institute executed an agreement with the University of California at Los Angeles (UCLA) for a 99 year affiliation. The purpose of this affiliation is to carry out the Institute's mission -- to further the conservation, improvement, and restoration of human eyesight -- through research, education, and clinical care (clinical care is provided directly by UCLA). Both the Institute and UCLA-Stein Eye Institute are dedicated to providing the public with the highest quality of ophthalmic care and the most innovative and strategic research for the improvement of human eyesight. IN NOV. 2021 DOHENY EYE INSTITUTE (DEI) MOVED TO ITS NEW LOCATION - 150 ORANGE GROVE BLVD IN PASADENA, CA. NEW AREAS OF RESEARCH DEI IS STUDYING THE MECHANISMS RESPONSIBLE FOR DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION (AMD), THE NUMBER ONE CAUSE OF BLINDNESS AMONG INDIVIDUALS OVER 60 YEARS OLD IN THE USA. THE RISK OF DEVELOPING AMD IS SIGNIFICANTLY INCREASED WHEN SPECIFIC GENES ARE MUTATED. ONE NEW STUDY IS FOCUSED ON STUDYING THE RETINAL CELLS IN THE POPULATION OF PATIENTS HARBORING A SPECIFIC MUTATION IN A GENE INVOLVED IN THE IMMUNE SYSTEM. A SECOND STUDY IS FOCUSED ON A DIFFERENT GENE OF UNKNOWN FUNCTION BUT WITH HIGH IMPACT ON AMD. THE RESEARCHERS ARE STUDYING RETINAL CELLS GENERATED FROM AMD PATIENTS THAT HAVE THESE GENETIC DEFECTS. INFORMATION FROM THESE TWO STUDIES IS CRITICAL FOR DEVELOPMENT OF NEW THERAPIES FOR AMD THAT TARGET WHAT IS CAUSING THE DISEASE. IN OTHER STUDIES, DEI SCIENTISTS HAVE BEEN INVOLVED IN DEVELOPING NEW AND FASTER WAYS TO INTERPRET RETINAL IMAGES IN HUMAN PATIENTS USING ARTIFICIAL INTELLIGENCE (AI). IN TWO DIFFERENT STUDIES, AI-BASED APPROACHES FOR AUTOMATED INTERPRETATION OF IMAGES FROM PATIENTS WITH RETINAL ATROPHY DUE TO EITHER STARGARDT'S DISEASE OR AMD INCORPORATES INFORMATION FROM MULTIPLE IMAGING MODALITIES. ADDITIONALLY, BY FOLLOWING PATIENT IMAGES OVER TIME, AN AI-BASED AUTOMATED ALGORITHM IS BEING DEVELOPED TO PREDICT THE DEVELOPMENT AND PROGRESSION OF ATROPHY OVER TIME. DEI CONTINUES TO DEVELOP CUTTING EDGE IMAGING TECHNOLOGY, INCLUDING A NOVEL ADAPTIVE OPTICS NEAR-CONFOCAL OPHTHALMOSCOPE (AONCO) THAT ENABLES PRECISE EVALUATION OF THE DYNAMIC MOVEMENT OF RED BLOOD CELLS WITHIN RETINAL CAPILLARIES, REFERRED TO AS "HIGHER-ORDER DYNAMICS". BY MONITORING RED BLOOD CELL VELOCITY WITHIN A CARDIAC CYCLE, THEY WILL OBTAIN CRUCIAL INFORMATION ABOUT VASCULAR HEALTH, NOT ONLY OF THE RETINA, BUT ALSO OF THE CENTRAL NERVOUS SYSTEM. THIS INSTRUMENT IS BEING USED TO ESTABLISH CLINICAL BIOMARKERS OF CEREBRAL SMALL VESSEL DISEASE, A PRECURSOR TO DEMENTIA. THIS WORK IS IMPORTANT BECAUSE IT DEMONSTRATES HOW THE RETINA CAN INFORM CLINICIANS ABOUT SYSTEMIC HEALTH, WHICH IS A NEW FIELD OF RESEARCH KNOWN AS "OCULOMICS". DEI HAS ALSO DEVELOPED A PIONEERING ADAPTIVE OPTICS IMAGING INSTRUMENT THAT INTEGRATES SCANNING LASER OPHTHALMOSCOPY AND OPTICAL COHERENCE TOMOGRAPHY (AO-SLO-OCT). THIS INSTRUMENT CAN IMAGE THE RETINA WITH A 3-D SPATIAL RESOLUTION, ALLOWING FOR IN-VIVO ULTRASTRUCTURE ASSESSMENT OF INDIVIDUAL PHOTORECEPTORS IN BOTH EN FACE AND CROSS-SECTIONAL PLANES. THE IMPORTANCE IS THAT THIS ADAPTIVE OPTICS IMAGING OVERCOMES THE LIMITATIONS PRESENTED BY OPTICAL DEFECTS IN LIVING EYES, ALLOWING FOR HIGH RESOLUTION IMAGES OF NOT ONLY PHOTORECEPTORS, BUT ALSO THE RETINAL PIGMENT EPITHELIAL CELLS AND THE CHORIOCAPILLARIS IN THE STUDY OF VARIOUS CHORIORETINAL DISEASES, INCLUDING AMD. ANOTHER IMAGING TECHNIQUE USED BY DEI SCIENTISTS IS THE USE OF CALCIUM IMAGING IN CONJUNCTION WITH CONFOCAL MICROSCOPY TO CHARACTERIZE THE EFFECTS OF OXIDATIVE STRESS ON THE RETINAL GANGLION CELLS. THESE EXPERIMENTS WILL IDENTIFY THE EARLY DEFICITS IN GANGLION CELL ELECTROPHYSIOLOGICAL FUNCTION RESULTING FROM MITOCHONDRIAL DYSFUNCTION. BY CAREFULLY ANALYZING THE EARLIEST SIGNS OF CHANGES TO PHOTORECEPTOR RESPONSE AND SYNAPTIC OUTPUT TO BIPOLAR CELLS, THIS DETECTION AND INTERPRETATION COULD LEAD TO DIAGNOSTIC CLUES THAT AID DETECTION OF PERSONS AT HIGHER RISK OF GLAUCOMA OR OPTIC NEUROPATHY. AN ADDITIONAL NEW AREA INVOLVES STUDIES AIMED AT UNDERSTANDING THE EARLY STAGES OF DIABETIC RETINOPATHY. INVESTIGATIONS ARE CENTERED AROUND HOW INFLAMMATION AND CELLS FROM THE IMMUNE SYSTEM CAN MEDIATED DEGENERATION OF INNER RETINAL VESSELS IN DIABETIC RETINOPATHY. THESE STUDIES, INTEGRATING VASCULAR BIOLOGY, IMMUNOLOGY, AND MECHANOBIOLOGY, HAVE LED TO A UNIQUE HYPOTHESIS THAT ALTERED VASCULAR STIFFNESS COULD BE KEY IN THE DEVELOPMENT OF EARLY DIABETIC RETINOPATHY. THIS FINDING IS IMPORTANT BECAUSE THE WORK, REVEALING A PREVIOUSLY UNRECOGNIZED MECHANISM UNDERLYING THE PATHOGENESIS, COULD LEAD TO EARLY TREATMENTS FOR DIABETIC RETINOPATHY. 12975041 true true false false false false false false false true true false false false true true true false false false false false false false false false false false false true false false false false false false false false false false false false false false false false false true 16 0 true 135 true true true false false false false false false false false false false false X 14 13 false false false false false false false true true false false true true true true true true true true false CA X X KASHIF KHAN 3233427100 150 ORANGE GROVE AVE PASADENA CA 91103 X MARISSA GOLDBERG CEO 50.0 0.0 X X 811410 0 74634 Deborah Ann Ferrington Chief Scientific Officer 37.5 0.0 X 433500 0 51120 SRINIVAS R SADDA MD Professor 37.5 0.0 X 276000 0 27600 MOLLY ANN WOODS Chief Dev. & Pub. Aff. Officer 37.5 0.0 X 231750 0 33506 KENT BERKELEY TEPPER IT DIRECTOR 37.5 0.0 X 196175 0 36238 STEVEN DANIEL MACGREGOR DIRECTOR OF FINANCE, TREASURER 37.5 0.0 X 178244 0 46468 Daniel Katz Administrative Director 37.5 0.0 X 162743 0 52958 Cecilia Zamudio Assoc. Dir. Comm., Secretary 37.5 0.0 X 105367 0 38527 JAMES GIPSON VICE CHAIRMAN 3.0 0.0 X X 0 0 0 CHARLES T FOSCUE CHAIRMAN 1.5 0.0 X X 0 0 0 ROBERT SMITH III DIRECTOR 0.25 0.0 X 0 0 0 JAY S WINTROB DIRECTOR 0.25 0.0 X 0 0 0 RONALD L OLSON DIRECTOR 0.25 0.0 X 0 0 0 STEPHEN A RALPH DIRECTOR 0.25 0.0 X 0 0 0 STEVEN E FELDON DIRECTOR 1.0 0.0 X 0 0 0 JOHN R CLEATOR DIRECTOR 0.25 0.0 X 0 0 0 KATHLEEN M DUNCAN DIRECTOR 0.25 0.0 X 0 0 0 GEOFFREY H GEE DIRECTOR 0.25 0.0 X 0 0 0 ERIC L SMALL DIRECTOR 0.25 0.0 X 0 0 0 ROBERT MALONEY DIRECTOR 0.25 0.0 X 0 0 0 MARK SAMUELS DIRECTOR 0.25 0.0 X 0 0 0 2395189 0 361051 8 false true false MAGINNIS KNECHTEL and McINTYRE LLP 300 W Colorado Blvd PASADENA CA 91105 AUDIT AND TAX 148450 1 2994217 3244324 6238541 CONTRACTS 900099 4962266 4962266 PASS THROUGH AWARDS 900099 676176 676176 OTHER REVENUE 900099 482714 465352 17362 6121156 2280634 2280634 0 91 91 1114338 1114338 0 1114338 1114338 138298058 134580168 3717890 3717890 3717890 0 0 0 0 0 0 0 0 0 0 19472650 6103794 17362 7112953 0 0 0 0 2756240 1501590 1254650 0 7319129 5324193 1349760 645176 574076 385114 148665 40297 2866107 1741923 929245 194939 632626 456013 130755 45858 0 330455 1730 328725 172525 172525 0 0 0 473288 16550 61439 395299 134352 1100 530 132722 1388113 208982 884821 294310 0 0 54915 54915 384285 346376 20094 17815 0 0 0 0 2531891 1265947 1240626 25318 379916 379916 MATERIALS AND SUPPLIES 1487620 805701 681919 UTILITIES 725482 725482 TELEPHONE 236089 17970 216999 1120 CONSORTIUM 899354 899354 59376 2498 48018 8860 23405839 12975041 8629084 1801714 X 35985510 2481219 0 0 1523933 1077846 2218448 2631573 0 0 0 0 0 0 0 0 445926 352538 120186069 10874390 107987321 109311679 89287583 128103962 0 0 0 0 0 0 4483728 4574624 241932449 248533441 10933531 13008217 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2804120 2440610 13737651 15448827 X 181656129 181876416 46538669 51208198 228194798 233084614 241932449 248533441 X -3933189 8596303 226702 X false true X true true true X 7080057 3578935 5232088 9662775 6238541 31792396 0 0 7080057 3578935 5232088 9662775 6238541 31792396 2801753 28990643 1122641 1291559 1522201 3713512 3395063 11044976 33375 12746 17362 63483 0 0 482000 0 0 482000 43382855 31638342 0.66825 0.66296 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 39668232 10000 7500551 2832672 44346111 34142711 2506000 5995644 2976123 39668232 32236904 5500 4558109 2657802 34142711 42699406 5000 -6980970 3486532 32236904 34555873 58765 10449330 2364562 42699406 0.00000 0.69480 0.30520 false false 25825643 25825643 74868155 6265255 68602900 8968626 4609134 4359492 10523644 10523644 109311679 0 REFUNDABLE ADVANCES 1772958 ANNUITY AGREEMENTS 667652 2440610 X 28295694 8596303 226741 8823044 19472650 19472650 23405878 39 39 23405839 23405839 INTENDED USES OF THE ORGANIZATION'S ENDOWMENT FUNDS SCH D PART V LINE 4 INTENDED USES OF THE ORGANIZATION'S ENDOWMENT FUNDS ARE TWOFOLD: 1. GENERATION OF FUNDS FOR RESEARCH PURPOSES; AND 2. GENERATION OF FUNDS FOR UNRESTRICTED PURPOSES. RECONCILIATION OF REVENUE SCH D PART XI, LINE 2D INCREASE IN VALUE OF SPLIT-INTEREST AGREEMENTS $ 226,741 SCH D PART XII, LINE 2D PENALTY ON FY24 CA TAXES ($ 39) FIN 48 FOOTNOTE SCH D PART X LINE 2 The Institute is a not-for-profit California corporation, granted tax-exempt status under Section 501(c)(3) of the Internal Revenue Code of 1986, as amended (the "Code"). The Institute is also exempt from California taxes, as a California Nonprofit Public Benefit Corporation. Accordingly, no provision has been made for income taxes. The Institute has analyzed its tax positions taken for filings with the Internal Revenue Service and State of California. It believes that its tax filing positions will be sustained upon examination and does not anticipate any adjustments that would result in a material adverse effect on its financial condition, results of operations or cash flows. The United States federal and State of California returns have statutes of limitations that generally range from three to four years. No open tax years are currently under examination. X X false false false false false false false false false MARISSA GOLDBERG CEO 572503 238907 34500 40134 886044 SRINIVAS R SADDA MD Professor 276000 27600 303600 STEVEN DANIEL MACGREGOR DIRECTOR OF FINANCE, TREASURER 178244 17824 28644 224712 KENT BERKELEY TEPPER IT DIRECTOR 196175 19618 16620 232413 Deborah Ann Ferrington Chief Scientific Officer 433500 34500 16620 484620 MOLLY ANN WOODS Chief Dev. & Pub. Aff. Officer 231750 4862 28644 265256 Daniel Katz Administrative Director 162743 16274 36684 215701 ANNUAL PERFORMANCE AND COMPENSATION REVIEW 990 PART VI LINE 15 Doheny Eye Institute conducts an annual performance and compensation review. This was last conducted in June, 2025. The Institute reviewed data for management positions using the "Non-Profit Compensation Report" 23rd Edition, 2023 by Candid (previously GuideStar). Any proposed salary for the CEO is reviewed, determined, and approved by the Doheny Eye Institute Executive Committee of the Board of Directors prior to taking effect. FORM 990 REVIEW 990 PART VI LINE 11A THE TAX PREPARER EMAILS A DRAFT COPY OF FORM 990 TO THE ORGANIZATION. THE DRAFT IS REVIEWED BY THE ORGANIZATION'S DIRECTOR OF FINANCE, CHIEF EXECUTIVE OFFICER, AND SENT TO THE BOARD OF DIRECTORS. COMMENTS AND QUESTIONS ARE EXCHANGED AND RESOLVED BOTH WITHIN THE ORGANIZATION AND BETWEEN THE ORGANIZATION AND THE TAX PREPARER. IF NECESSARY, A SECOND DRAFT IS CIRCULATED PRIOR TO ISSUING THE FINAL FORM 990 TO BE FILED. PUBLIC DISCLOSURE 990 PART VI LINE 19 The Organization's governing documents, conflict of interest policy, and recent federal income tax returns are made available for public inspection at the Organization's principal office during normal business hours. OTHER CHANGES IN NET ASSETS OR FUND BALANCES 990 PART XI LINE 9 CHANGE IN VALUE OF SPLIT-INTEREST AGREEMENTS: $ 226,741 PENALTY FROM FY24 ($ 39) --------------- TOTAL $ 226,702 CONFLICT OF INTEREST POLICY 990 PART VI LINE 12 Officers, directors, and key employees are required to complete and submit a conflict of interest questionnaire annually. The forms are tracked and reviewed by the executive committee. Should conflicts arise mid-year, according to the policy, the officer, director, or key employee would immediately be required to: (i) disclose the existence and circumstances of any transaction or relationship that could give rise to an actual or apparent conflict of interest with DEI, (ii) refrain from using personal influence to encourage DEI to take an action or decline to take an action involving such a transaction or relationship and (iii) recuse himself or herself from participation in any discussions or decisions regarding such transaction or relationship with directors, officers or key employees of DEI. This includes recusal during those portions of Board, Executive Committee or other Board committee meetings in which matters pertaining to such a transaction or relationship are being discussed, except to respond to requests for information about the transaction or relationship. Should any suspected or reported violations be found, the Chairman of the Board of Directors would promptly be notified and would then recommend appropriate action to the Executive Committee or the Board.